Marizomib

• CAT Number: R036162
• CAS Number: 437742-34-2
• Molecular Formula: C15H20ClNO4
• Molecular Weight: 313.78
• Purity: ≥95%
• Synonyms: (1R,4R,5S)-4-(2-Chloroethyl)-1-[(S)-(1S)-2-cyclohexen-1-ylhydroxymethyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione; (-)-Salinosporamide A; ML 858; NPI 0052; Salinosporamide A
• Target: Proteasome
• Solubility: Soluble in DMSO
• Storage: Store at -20°C
• IUPAC Name: (1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-[(1S)-cyclohex-2-en-1-yl]-hydroxymethyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
• InChI: InChI=1S/C15H20ClNO4/c1-14-10(7-8-16)12(19)17-15(14,13(20)21-14)11(18)9-5-3-2-4-6-9/h3,5,9-11,18H,2,4,6-8H2,1H3,(H,17,19)/t9-,10+,11+,14+,15+/m1/s1
• InChIKey: NGWSFRIPKNWYAO-SHTIJGAHSA-N
• SMILES: CC12C(C(=O)NC1(C(=O)O2)C(C3CCCC=C3)O)CCCl

Marizomib（Cat No.:R036162）is a potent, naturally derived proteasome inhibitor isolated from the marine bacterium Salinispora tropica. It functions by irreversibly inhibiting all three proteolytic activities of the 20S proteasome, making it a powerful anti-cancer agent. Marizomib is particularly effective against multiple myeloma and solid tumors, where it disrupts protein homeostasis, leading to cancer cell death. Its unique mechanism offers advantages over other proteasome inhibitors, showing promise in overcoming drug resistance. Ongoing clinical trials are exploring its efficacy and safety, aiming to enhance cancer treatment regimens and improve patient outcomes.